Bajaj Healthcare has reportedly launched Posaconazole API which is used in the treatment of mucormycosis (black fungus) infection in COVID-19 patients.
According to reports, a regulatory filing by Bajaj Healthcare states that the company has received approval from FDA (Food and Drugs Administration) Gandhi Nagar, Gujarat, to manufacture and market Posaconazole API as approved medication for treating Mucormycosis in India.
The company said it will commence commercial production from the first week of June 2021. Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients.
More than 11,000 cases of black fungal infection have been reported from different parts of the country and have been seen in patients recovering from COVID-19.
The company said FDA Gandhi Nagar, Gujarat (India) has granted permissions to manufacture and market the Posaconazole API in the domestic as well as overseas market.
